)
Edge10 Jul 2026
Inside Take-Two: The Grand Anticipation
The story of how Take-Two Interactive built the empire behind Grand Theft Auto, Red Dead Redemption, and one of gaming's largest mobile portfolios.
KYORIN Pharmaceutical
KYORIN Pharmaceutical (4569) investor relations material
KYORIN Pharmaceutical Q1 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2027 earnings summary30 Jul, 2026
Executive summary
Net sales for FY2026 1Q decreased by 1.9% year-over-year to ¥29,654 million, mainly due to lower sales of new drugs in Japan and overseas, despite growth in Beova and generic drugs.
Operating profit dropped 59.3% year-over-year to ¥964 million, impacted by higher R&D expenses and increased SG&A costs.
Profit attributable to owners of parent fell 60.8% year-over-year to ¥824 million.
Comprehensive income fell sharply by 98.5% to ¥30 million for the quarter.
Financial highlights
Net sales: ¥29,654 million (down ¥575 million year-over-year).
Operating profit: ¥964 million (down ¥1,404 million year-over-year).
Ordinary profit: ¥1,241 million (down ¥1,382 million year-over-year).
Basic earnings per share for the quarter were ¥14.35, down from ¥36.57 a year earlier.
Equity ratio improved to 74.4% from 72.9% at the end of the previous fiscal year.
Outlook and guidance
FY2026 interim and full-year forecasts remain unchanged: net sales forecast at ¥57,800 million (interim) and ¥121,800 million (full year).
Full-year profit attributable to owners of parent is projected at ¥1,500 million, down 56.5% year-over-year.
Earnings per share for the full year are forecast at ¥26.11.
Annual dividend plan maintained at ¥25 per share.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from KYORIN Pharmaceutical
- Q1 FY2024 delivered higher sales and profits, but FY2025 profit is forecast to decline.4569
Q1 202515 May 2026 - New drug growth lifted sales and profits, but net income and comprehensive income declined.4569Q2 202515 May 2026
- Profits surged on new drug growth and a major licensing payment; next year sees lower outlook.4569Q4 202515 May 2026
- Sales and operating profit rose, but net profit and comprehensive income fell sharply year-over-year.4569Q3 202515 May 2026
- Strong nine-month results, but full-year outlook projects lower sales and profits.4569Q3 202615 May 2026
- Strong Q1 profit growth, but full-year outlook projects lower sales and earnings.4569Q1 202615 May 2026
- Net sales and profits rose in 1H, but full-year earnings are forecast to decline sharply.4569Q2 202615 May 2026
- Profits and sales declined sharply, with further decreases forecast for the next fiscal year.4569Q4 202615 May 2026
Next KYORIN Pharmaceutical earnings date
Q2 202710 Nov, 2026
KYORIN Pharmaceutical
Next KYORIN Pharmaceutical earnings date
Q2 202710 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage